Ovid Therapeutics (OVID) Debt to Equity (2019 - 2020)
Ovid Therapeutics (OVID) reported Debt to Equity of $0.06 for Q4 2020, up 1212.65% on a YoY basis from $0.0 in Q1 2020, and up 1132.97% quarter-over-quarter from $0.0 in Q3 2020.
Ovid Therapeutics (OVID) Debt to Equity (2019 - 2020) Analysis & Trends
Ovid Therapeutics has reported Debt to Equity for 2 years, with the latest figure at $0.06 in Q4 2020.
- For the quarter ending Q4 2020, Debt to Equity rose 1212.65% year-over-year to $0.06; the trailing twelve-month figure through Dec 2020 stood at $0.06 (up 1212.65% YoY), and the FY2020 full-year result was $0.06, up 1212.65% from the prior year.
- Debt to Equity for Q4 2020 stood at $0.06, up from $0.0 in the prior quarter.
- The five-year high for Debt to Equity was $0.06 in Q4 2020, with the low at $0.0 in Q4 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt/Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 0.32 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Ovid Therapeutics | 311.83 Mn | 156.31 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 0.06 |
| Sep 30, 2020 | 0.00 |
| Jun 30, 2020 | 0.01 |
| Mar 31, 2020 | 0.01 |
| Dec 31, 2019 | 0.00 |
| Sep 30, 2019 | 0.02 |
| Jun 30, 2019 | 0.03 |
| Mar 31, 2019 | 0.02 |